Spevatamig (PT886) Trial
Phase 1/2
258
about 5.1 years
18+
11 sites in CA, CO, IA +7
What this study is about
This trial is testing Spevatamig (PT886), a treatment, as a single drug or in combination with chemotherapy and/or immunotherapy. The goal is to see if Spevatamig is safe and effective for people with advanced stomach cancer, gastroesophageal junction cancer, bile duct cancer, or pancreatic cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Abraxane
- 2.Take Capecitabine
- 3.Take FOLFIRINOX
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
capecitabine, chemotherapy, fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), gemcitabine, immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), oxaliplatin, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
oral (Oral Tablet), infusion, oral (Oral Capsule), injection (Injection), injection, intravenous
Primary: To determine the dose-limiting toxicity (DLT) of Spevatamig (PT886)., To determine the maximum tolerated dose (MTD) of Spevatamig (PT886)., To evaluate the safety and tolerability of Spevatamig (PT886).
Secondary: To evaluate the pharmacokinetics of Spevatamig (PT886).
Oncology, Gastroenterology